

Cytotoxic 9,19-cycloartane triterpenoids from the roots of *Cimicifuga foetida* L.



Guo-Lei Zhu^{a,b}, Yin Nian^a, Di-Fan Zhu^c, Luo-Sheng Wan^{a,b}, Ni-Man Bao^{a,b}, Wei-Hua Wang^{a,b}, Lin Zhou^a, Ming-Hua Qiu^{a,*}

^a State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences (CAS), Kunming 650204, PR China

^b Graduate University of Chinese Academy of Sciences, Beijing 100049, PR China

^c Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, PR China

ARTICLE INFO

Article history:

Received 24 February 2016

Received in revised form 10 May 2016

Accepted 6 June 2016

Available online 29 September 2016

Keywords:

Cimicifuga foetida L.

9,19-Cycloartane triterpenoids

Cytotoxicity

ABSTRACT

Eight new cycloartane triterpenoids (**1–8**), along with eight known analogues (**9–16**), were isolated from the roots of *Cimicifuga foetida* L. Their structures were elucidated by spectroscopic analysis and acidic hydrolysis. All of the new compounds were evaluated for their in vitro cytotoxicity against five human tumor cell lines (HL-60, SMMC-7721, A-549, MCF-7 and SW480), and compound **2** showed inhibitory activities with IC₅₀ values ranging from 2.61 to 3.32 μM.

© 2016 Phytochemical Society of Europe. Published by Elsevier Ltd. All rights reserved.

1. Introduction

The genus *Cimicifuga* (Ranunculaceae family) or *Actaea* contains 28 species, whose roots have been used in traditional medicine since ancient times in China (Compton et al., 1998; Li and Yu, 2006). Currently, three species (*C. heracleifolia*, *C. dahurica*, *C. foetida*) of this genus are listed officially as a cooling and detoxifying remedy in the Chinese Pharmacopoeia 2010, respectively (Pharmacopoeia of the People's Republic of China, 2010). Additionally, the theory of traditional Chinese medicine defines a tumor as a kind of toxin (Tian et al., 2007). So it is interest to explore potential antitumor constituents of *Cimicifuga* based on the theory of TCM and the function of *Cimicifuga*.

Our previous phytochemical investigation led to isolation of a series of new 9,19-cycloartane triterpenes and their glycosides from *C. foetida* L., some of which showed significant cytotoxicities against different tumor cell lines (Nian et al., 2010, 2011, 2012; Lu et al., 2012). As a continuing efforts to study this source, eight new 9,19-cycloartane triterpenoids, namely cimiacerol-1(2)-en-3-one (**1**), 25-*O*-methyl-24-*O*-acetylisodahurinol-3-*O*-β-*D*-xylopyranoside (**2**), 12-*O*-acetyl-25-anhydrocimicigenol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside (**3**), 2'-*O*-acetylcimicigenol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside (**4**), cimilactone K

(**5**), 4',23-*O*-diacetylshengmanol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside (**6**), 26-deoxyacetylacteol-7(8)-en-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside (**7**), and acteol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside, together with eight known compounds (**9–16**) (Fig. 1.) were further isolated. New compounds were tested for their cytotoxicities against human tumor HL-60, SMMC-7721, A-549, MCF-7 and SW480 cell lines, using the MTT assay. We herein reported the isolation, structure elucidation, and biological activities of these compounds.

2. Results and discussion

The molecular formula of compound **1** was identified as C₃₀H₄₄O₅ by its HR-EIMS at *m/z* 484.4168 [M]⁺. The UV (268 nm) and IR (1667, 1641 cm⁻¹) spectra of **1** indicated the presence of α,β-unsaturated carbonyl. The analysis of ¹H NMR spectrum of **1** showed the characteristic cyclopropane methylene signals at δ_H 0.62 and 1.15 (each 1H, d, *J* = 4.4 Hz), two olefinic protons at δ_H 6.77 and 6.16 (each 1H, d, *J* = 10.1 Hz), a secondary methyl at δ_H 1.24 (3H, d, *J* = 6.4 Hz), and five tertiary methyls at δ_H 0.83–1.79 (each 3H, s). The ¹³C NMR and DEPT spectroscopic data (Table 2) of **1** displayed a typical cimiaceroside-type carbon resonances, corresponding to the methylene carbon of the cyclopropane ring at C-19 (δ_C 30.0), three oxymethine carbons at C-16 (δ_C 72.5), C-22 (δ_C 87.2), and C-24 (δ_C 83.6), two oxygenated quaternary carbons at C-23 (δ_C 106.4) and C-25 (δ_C 84.0), as well as an α, β-unsaturated carbonyl unit at δ_C 154.3 (d), 127.2 (d), and 204.5 (s). These data were similar to

* Corresponding author.

E-mail address: mhchiu@mail.kib.ac.cn (M.-H. Qiu).




Fig. 1. The structures of compounds 1–16.

those of **9** (Kusano et al., 1998). However, a detailed comparison of their 1D NMR spectra revealed that the α,β -unsaturated ketone moiety at δ_C 154.3, 127.2, and 204.5 of **1** replaced a saturated system at C-1 (δ_C 30.4, t), C-2 (δ_C 29.6, t), and C-3 (δ_C 88.2, d) of **9**. This deduction was further confirmed by the HMBC correlations (Fig. 2) of H-1 (δ_H 6.77) with C-3 (δ_C 204.5), C-5 (δ_C 45.1), and C-9 (δ_C 24.8), of H-2 (δ_H 6.16) with C-4 (δ_C 46.5) and C-10 (δ_C 30.6), of H₃-29 (δ_H 1.21) and H₃-30 (δ_H 0.97) with C-3, together with the ¹H–¹H COSY correlation of H-1 (δ_H 6.77, J = 10.1 Hz) and H-2 (δ_H 6.16, J = 10.1 Hz).

The cross peaks of H-5 (δ_H 2.05), H-16 (δ_H 4.99), and H-17 (δ_H 1.58) with H₃-28 (δ_H 0.97), of H₃-21 and H₃-26 with H-22 (δ_H 3.91), and of H₃-26 with H-24 in the ROESY spectrum (Fig. 2) randomly indicated H-5, H-16, H-17, H-22, H-24 and H₃-26 to be an α -directed, whereas the associations of H-8 (δ_H 1.92) and H-20 (δ_H 2.30) with H₃-18 (δ_H 1.17) suggested that the H-8 and H-20 were β -orientations. The deshielded chemical shifts of C-22 (δ_C 87.2), C-23 (δ_C 106.4), and C-24 (δ_C 83.6) indicated the 23*S*, 24*R* configurations in **1**, compared to the 23*S*, 24*R* configurations [C-22 (δ_C 86.8), C-23 (δ_C 106.1), and C-24 (δ_C 83.3)] (Kusano et al.,




Fig. 2. Major figure HMBC (→), ¹H–¹H COSY (→), and ROESY (↔) correlations of **1**.

Table 1¹H NMR data of Compounds **1–8** in pyridine-*d*₅ at 600 MHz (δ in ppm, *J* in Hz).

No.	1	2	3	4	5	6	7	8
1	6.77 d (10.1)	1.17 m 1.53 m	1.09 m 1.56 m	1.20 m 1.57 m	1.08 t (13.1) 1.48 t (10.8)	1.26 m 1.62 m	1.09 m 1.53 m	1.10 m 1.49 m
2	6.16 d (10.1)	2.38 m 1.94 m	1.87 m 2.26 m	1.88 dd (3.8, 12.5) 2.24 m	1.82 m 2.23 m	1.97 m 2.34 m	1.81 m 2.16 m	1.80 m 2.20 m
3	–	3.53 dd (4.3, 11.6)	3.48 dd (4.3, 11.6)	3.39 dd (4.4, 11.7)	3.44 dd (4.1, 11.7)	3.50 dd (4.0, 11.8)	3.37 dd (3.7, 11.4)	3.40 dd (4.9, 11.6)
5	2.05 dd (12.7, 3.5)	1.30 dd (4.2, 12.5)	1.28 dd (4.1, 12.4)	1.31 dd (4.4, 12.5)	1.23 m	1.36 m	1.12 m	1.19 m
6	1.38 m 1.09 m	0.60 m 1.46 m	0.72 dd (12.4, 24.9) 1.59 m	0.71 dd (11.6, 24.1) 1.53 m	0.70 dd (12.5, 25.0) 1.49 m	0.76 dd (12.7, 24.9) 1.61 m	1.75 m 2.08 m	0.64 m 1.38 m
7	1.34 m 1.06 m	0.60 dd (12.3, 24.6) 1.31 m	1.12 m 2.23 m	1.14 m 2.11 m	0.93 m 1.23 m	2.11 ^a	5.08 ^a	0.87 m 1.15 ^a
8	1.92 dd (9.6, 7.1)	1.71 dd (4.2, 12.9)	1.75 dd (4.4, 24.9)	1.68 m	1.59 dd (5.0, 11.6)	1.86 m	–	1.57 m
11	1.56 m 1.10 m	1.02 m 2.27 m	1.14 m 2.95 dd (9.4, 16.1)	1.03 m 2.06 m	1.15 dd (3.1, 16.1) 2.71 dd (9.0, 16.1)	1.16 m 2.14 m	1.21 m 2.91 dd (9.6, 16.0)	1.16 ^a 2.69 dd (9.1, 16.1)
12	1.58 m 1.49 m	1.35 m 1.60 m	5.26 dd (2.5, 9.4)	1.53 m 1.69 m	5.07 m	1.81 m 18.1 m	5.20 d (8.4)	5.07 dd (3.9, 8.6)
15	1.88 dd (12.0, 7.9) 1.61 m	–	4.45 s	4.31 m	1.82 m 2.00 m	4.36 br s	2.08 (2H, m)	1.72 m 1.89 m
16	4.99 dd (12.0, 7.9)	3.79 d (11.8)	–	–	4.80 dd (7.4, 19.5)	–	4.30 m	4.6 dd (7.2, 14.6)
17	1.58 m	1.57 m	1.64 m	1.52 m	2.15 d (8.5)	2.34 d (6.4)	1.75 m	1.76 m
18	1.17 s	1.20 s	1.32 s	1.16 s	1.24 s	1.40 s	1.46 s	1.34 s
19	1.15 d (4.4) 0.62 d(4.4)	0.26 d (4.1) 0.49 d (3.8)	0.29 d (4.0) 0.58 d (3.5)	0.24 d (4.0) 0.47 d (3.7)	0.18 d (3.8) 0.55 d (3.2)	0.29 d (3.5) 0.56 d (3.5)	0.46 d (7.4) 0.82 m	0.19 d (4.0) 0.54 d (3.6)
20	2.30 m	1.81 m	1.64 m	1.68 m	2.0 m	2.11 m	2.20 m	1.81 m
21	1.24 d (6.4)	0.92 d (6.4)	0.95 d (5.2)	0.87 d (6.5)	0.97 d (6.2)	1.25 d (6.5)	0.99 d (6.4)	0.94 d (6.3)
22	3.91 d (10.7)	1.42 m 1.67 m	1.00 m 2.24 m	1.05 m 2.30 m	2.27 t (13.8) 2.47 dd (3.0, 14.7)	1.75 m 2.67 t (12.8)	1.41 d (9.4) 1.57 m	1.66 m 2.20 m
23	–	4.03 m	4.31 d (9.4)	4.79 d (10.4)	–	5.39 br t (8.4)	–	–
24	4.21 br s	5.30 d (2.2)	4.19 br s	3.80 br s	–	3.02 d (8.4)	3.66 br s	3.93 br s
26	1.79 s	1.43 s	4.90 s 5.38 s	1.49 s	–	1.34 s	3.60 d (10.4) 4.04 m	5.74 br s
27	1.71 s	1.46 s	1.86 s	1.52 s	–	1.36 s	1.45 s	1.77 s
28	0.83 s	1.46 s	1.22 s	1.20 s	0.84 s	1.22 s	1.02 s	0.77 s
29	1.21 s	1.33 s	1.32 s	1.10 s	1.32 s	1.24 s	1.29 s	1.28 s
30	0.97 s	1.04 s	1.04 s	0.98 s	1.01 s	1.08 s	0.97 s	0.98 s
CH ₃ CO-12			2.13 s		2.14 s		2.16 s	2.13 s
CH ₃ CO-23						2.04 s		
CH ₃ CO-24		2.17 s						
CH ₃ O-25		3.23 s						
sugar								
1'		4.88 d (7.6)	4.82 d (7.6)	4.80 d (8.1)	4.82 d (7.2)	4.83 d (7.6)	4.77 d (7.2)	4.79 d (7.5)
2'		4.07 t (8.0)	4.07 dd (7.4, 15.1)	5.54 t (8.1)	4.07 m	4.08 m	4.03 m	4.03 m
3'		4.19 t (8.8)	4.16 m	4.09 t (9.1)	4.16 m	4.08 m	4.12 m	4.13 m
4'		4.26 m	4.12 m	4.19 m	4.13 m	4.15 m	4.10 m	4.18 m
5'		3.75 d (10.6) 4.39 dd (5.2, 11.3)	3.67 t (10.8) 4.34 m	3.65 t (11.3) 4.19 m	3.70 m 4.34 m	3.72 m 4.36 m	3.59 m 4.03 m	3.68 m
1''			5.33 d (7.7)	4.92 d (7.8)	5.33 d (7.7)	5.31 d (7.4)	5.30 d (7.3)	5.29 d (7.6)
2''			4.31 m	3.91 m	4.07 dd (7.4, 15.1)	4.09 m	4.31 m	4.03 m
3''			4.18 m	4.13 t (8.8)	4.18 m	4.18 m	4.15 m	4.15 m
4''			4.20 m	4.04 m	4.20 m	4.21 m	4.17 m	4.16 m
5''			3.72 t (13.6) 4.34 m	3.76 t (10.7) 4.32 m	3.70 m 4.34 m	3.72 m 4.36 m	3.59 m 4.03 m	3.68 m 4.31 m
CH ₃ CO –2'				2.36 s				

^a Signals overlapped.

Table 2
 ^{13}C DEPT data of compounds **1–8** in pyridine- d_5 at 150 Hz (δ in ppm).

No.	1	2	3	4	5	6	7	8
1	154.3 d	32.9 t	32.8 t	32.3 t	31.9 t	32.5 t	30.5 t	31.9 t
2	127.2 d	30.6 t	30.5 t	30.3 t	29.9 t	30.4 t	29.8 t	29.9 t
3	204.5 s	88.3 d	88.9 d	89.4 d	88.3 d	88.9 d	88.4 d	88.3 d
4	46.5 s	41.8 s	41.8 s	41.4 s	41.2 s	41.8 s	40.7 s	41.2 s
5	45.1 d	47.8 d	47.6 d	47.5 d	46.9 d	47.7 d	42.7 d	46.9 d
6	24.4 t	21.2 t	21.2 t	21.1 t	20.4 t	21.3 t	22.1 t	20.4 t
7	20.0 t	26.5 t	26.5 t	26.5 t	25.6 t	27.0 t	114.4 d	25.6 t
8	44.0 d	44.1 d	47.7 d	49.0 d	45.9 d	48.6 d	147.7 s	45.6 d
9	24.8 s	20.4 s	20.6 s	20.3 s	20.7 s	20.4 s	21.6 s	20.1 s
10	30.6 s	27.5 s	27.2 s	26.8 s	26.8 s	27.0 s	28.5 s	26.7 s
11	27.9 t	26.3 t	38.0 t	26.8 t	36.4 t	26.3 t	36.9 t	36.7 t
12	33.3 t	31.8 t	77.8 d	34.3 t	76.6 d	33.3 t	77.1 d	77.1 d
13	47.6 s	40.3 s	46.5 s	42.2 s	48.3 s	41.7 s	50.8 s	48.7 s
14	45.6 s	55.4 s	48.8 s	47.6 s	48.6 s	46.4 s	48.4 s	48.0 s
15	42.8 t	214.5 s	79.8 d	80.4 d	43.8 t	83.2 d	43.4 t	43.6 t
16	72.5 d	84.7 d	112.7 s	112.3 d	80.4 d	220.1 s	74.9 d	73.0 d
17	52.5 d	52.3 d	60.0 d	59.9 d	53.6 d	60.2 d	56.9 d	56.4 d
18	20.1 q	20.7 q	13.2 q	19.8 q	13.3 q	19.7 q	15.2 q	13.6 q
19	30.0 t	31.6 t	31.4 t	31.0 t	29.6 t	30.8 t	29.1 t	29.5 t
20	35.1 d	33.6 d	24.4 d	24.4 d	26.8 d	28.2 d	23.5 d	26.0 d
21	17.9 q	20.4 q	20.2 q	19.8 q	22.2 q	20.6 q	21.7 q	21.7 q
22	87.2 d	39.0 t	39.0 t	38.4 t	38.6 t	37.3 t	37.5 t	37.6 t
23	106.4 s	78.9 d	75.0 d	72.3 d	173.7 s	72.4 d	106.3 s	105.9 s
24	83.6 d	77.3 d	87.0 d	90.7 d		65.5 d	62.7 d	63.5 d
25	84.0 s	77.5 s	146.3 s	71.3 s		58.9 s	62.8 s	65.6 s
26	28.2 q	21.9 q	113.7 t	25.6 q		25.8 q	68.5 t	98.4 d
27	25.2 q	23.8 q	18.6 q	27.5 q		19.7 q	14.6 q	13.1 q
28	19.2 q	18.0 q	12.5 q	12.3 q	19.9 q	12.3 q	27.2 q	19.5 q
29	22.2 q	26.1 q	26.0 q	25.6 q	15.5 q	25.0 q	25.9 q	25.5 q
30	19.7 q	15.9 q	15.9 q	15.9 q	25.6 q	15.8 q	14.6 q	15.3 q
CH ₃ CO-12			171.0 s		170.7 s		170.8 s	170.6 s
CH ₃ CO-12			22.2 q		21.5 q		21.4 q	21.7 q
CH ₃ CO-23						170.7 s		
CH ₃ CO-23						21.0 q		
CH ₃ CO-24		171.3 s						
CH ₃ CO-24		21.4 q						
CH ₃ O-25		49.70 q						
sugar								
1'		108.1 d	107.6 d	105.0 d	107.2 d	107.5 d	107.4 d	107.2 d
2'		76.1 d	75.9 d	73.8 d	74.1 d	75.7 d	75.8 d	74.6 d
3'		79.2 d	87.8 d	85.4 d	87.4 d	87.7 d	87.4 d	87.4 d
4'		71.7 d	69.8 d	71.3 d	69.3 d	69.6 d	69.7 d	71.0 d
5'		67.6 t	67.1 t	66.9 t	66.6 t	66.9 t	67.0 t	66.6 t
1''			106.7 d	106.8 d	106.3 d	106.5 d	106.6 d	106.3 d
2''			75.0 d	74.7 d	75.4 d	74.8 d	74.9 d	75.4 d
3''			78.8 d	79.0 d	78.3 d	78.6 d	78.7 d	78.3 d
4''			71.5 d	69.8 d	71.0 d	71.3 d	71.4 d	69.4 d
5''			67.9 t	67.8 t	67.5 t	67.7 t	67.8 t	67.5 t
CH ₃ CO-2'				170.4 s				
CH ₃ CO-2'				21.8 q				

1998), and 23S, 24S configurations [C-22 (δ_{C} 84.9), C-23 (δ_{C} 103.0), and C-24 (δ_{C} 81.8)] (Chen et al., 2014). Thus, the structure of **1** was elucidated as cimiacerol-1(2)-en-3-one.

Compound **2** gave the molecular formula of $\text{C}_{38}\text{H}_{60}\text{O}_{10}$, as determined by HR-ESIMS ($[\text{M}+\text{Na}]^+$ at m/z 699.4074; calcd for $\text{C}_{38}\text{H}_{60}\text{O}_{10}\text{Na}$, 699.4084). Apart from the signals for an acetyl group,

a methoxy group, and a xylose unit, 30 signals of the aglycone were assigned as 7 methyls, 8 methylenes, 8 methines, and 7 quaternary carbons (Table 2) based on its 1D NMR and HSQC spectra. The 1D NMR data of **2** (Tables 1 and 2) displayed the structural resemblance with those of 24-O-acetylisdahurinol-3-O- β -D-xylopyranoside (Shao et al., 2000), except for the occurrence of




Fig. 3. Major HMBC (→), ^1H - ^1H COSY (→), and ROESY (↔) correlations of **3**.

a methoxy group in **2**. The substituent methoxy group was attached at C-25 by the observation of HMBC correlation of the methoxyl proton (d_H 3.23) with C-25 (d_C 77.5). Furthermore, the absolute configuration of C-24 was determined to be *S* by comparison of the coupling constants of H-24 ($J=2.2$ Hz) of **2** with those of dahurinyl diacetate ($J=9.0$ Hz) and isodahurinyl diacetate ($J=2.0$ Hz) (Kusano et al., 1976). Therefore, the structure of **2** was elucidated as 25-*O*-methyl-24-*O*-acetylisodahurinol-3-*O*- β -D-xylopyranoside.

Compound **3** possessed a molecular formula of $C_{42}H_{64}O_{14}$ as determined by the HR-ESIMS at m/z 815.4180 $[M+Na]^+$. The 1D NMR data (Tables 1 and 2) of **3** showed that **3** resembled 25-anhydrocimicigenol-3-*O*-[2'-*O*-acetyl]- β -D-xylopyranoside (Zhou et al., 2006) with the major differences of the sugar unit and an additional acetoxy group of the aglycone. Among them, the acetoxy [d_C 171.0 (s), 22.2 (q); d_H 2.13 (3H, s)] was located at C-12, which was confirmed by the HMBC correlation (Fig. 3) of H-12 (δ_H 5.26) with the acetyl carbonyl carbon (δ_C 171.0), together with the spin system of H-12/H₂-11 (δ_H 1.14, 2.95) deduced from a COSY experiment (Fig. 3). Meanwhile, its relative configuration was determined as β -orientation through the significant ROESY correlations (Fig. 3) of H-12 with H-17 (d_H 1.64) and H₃-28 (d_H 1.22).

Moreover, the 1H NMR spectrum displayed two anomeric protons at d_H 4.82 (d, $J=7.6$ Hz) and 5.33 (d, $J=7.7$ Hz), in accordance with two glycosidic moieties [d_C 107.7 (C-1'), 75.9 (C-2'), 87.8 (C-3'), 69.8 (C-4'), 67.1 (C-5'); 106.7 (C-1''), 75.0 (C-2''), 78.8 (C-3''), 71.5 (C-4''), 67.9 (C-5'')] were observed in the ^{13}C NMR spectrum. The sugar obtained after acid hydrolysis was unambiguously identified as D-xylose by comparing its TLC and specific rotation with a standard. HMBC correlations of H-1' with C-3 and H-1'' with C-3' implied that the disaccharide unit attached to C-3 of the aglycone and the terminal xylosyl to C-3' of the inner xylosyl, respectively. Furthermore, the relative configuration of H-1' and H-1'' were determined to be β orientations on the basis of the coupling constants ($J=7.6, 7.7$ Hz) of the anomeric proton signals. Thus, the structure of **3** was elucidated as 12-*O*-acetyl-25-anhydrocimicigenol-3-*O*- β -D-xylopyranosyl-3'-*O*- β -D-xylopyranoside.

Compound **4**, a white powder, gave a pseudo-molecular ion at m/z 817.4339. $[M+Na]^+$ in HR-ESIMS, corresponding to the molecular formula of $C_{42}H_{66}O_{14}$. The 1D NMR spectroscopic data (Table 2) of **4** showed that the aglycone of **4** were identical with that of cimigenol-3-*O*-[2'-*O*-acetyl]- β -D-xylopyranoside (Nian et al., 2011). Meanwhile, the presence of 2'-*O*-acetyl- β -D-xylopyranose fraction was deduced by comparing the 1D NMR data between **4** and cimigenol-3-*O*-[2'-*O*-acetyl]- β -D-xylopyranoside. However, another pentosyl signals [δ_C 106.8 (C-1''), 74.7 (C-2''), 79.0 (C-3''), 69.8 (C-4''), 67.8 (C-5'')] were observed in its 1D NMR spectra of **4**. Moreover, this sugar moiety was connected to C-3' via an ether bond based on the HMBC correlations (Fig. 4) of H-3'' with C-3' (δ_C 105.0). Similarly, this sugar was identified as D-xylose by

using above method. Moreover, the configurations of the two xylosyl moieties were both determined as β on the basis of the coupling constants ($J=7.2, 7.7$ Hz) of the anomeric protons. Hence, the structure of compound **4** was determined to be 2'-*O*-acetylcimigenol-3-*O*- β -D-xylopyranosyl-3'-*O*- β -D-xylopyranoside.

The molecular formula of compound **5** was assigned as $C_{38}H_{58}O_{13}$ by the HR-ESIMS at m/z 745.3765 $[M+Na]^+$. Comparison of the 1D NMR spectroscopic data (Tables 1 and 2) of **5** with those of cimilactone A (Liu et al., 2002) revealed that they had the similar structures, and the only difference was the sugar moieties. Moreover, the sugar moieties was determined to be 3-*O*- β -D-xylopyranosyl-3'-*O*- β -D-xylopyranoside unit by comparing to the 1D NMR data of **3** (Tables 1 and 2) and analysis of their 2D NMR correlations. Accordingly, the structure of **5** was finally elucidated as shown and named cimilactone K.

Compound **6** was obtained as a white powder. Its molecular formula was determined to be $C_{42}H_{66}O_{14}$ (817.4342 $[M+Na]^+$, calcd 817.4350) by its HR-ESIMS. Detailed comparison the 1D NMR data of **6** (Tables 1 and 2) with those of 4',23-*O*-diacetylshengmanol-3-*O*- β -D-xylopyranoside (Chen et al., 2002a,b) showed that they were similar in structure except for signal of the sugar moieties. The NMR data of the sugar residues of **6** agreed well with those of **3**. Moreover, the correlations of an anomeric proton H-1' (δ_H 4.83) with C-3 (δ_C 88.9), and of another anomeric proton H-1'' (δ_H 5.31) with C-3' (δ_C 87.7) in the HMBC spectrum, indicated that the inner xylosyl attached to C-3 of the aglycone and the terminal xylosyl to C-3' of the inner xylosyl. The configuration of C-23 and C-24 were determined as *R* and *S*, respectively, by comparing the known 9,19-cycloartane triterpene glycosides (Kusano et al., 1999). Thus, the structure of **6** was characterized as 4', 23-*O*-diacetylshengmanol-3-*O*- β -D-xylopyranosyl-3'-*O*- β -D-xylopyranoside.

The HR-ESIMS (813.4029 $[M+Na]^+$, calcd 813.4037) of compound **7** suggested a molecular formula of $C_{42}H_{62}O_{14}$. The 1D NMR data (Tables 1 and 2) of **7** were similar to those of 26-deoxyactein (Chen et al., 2002a,b), except for the presence of an additional double bond and an monosaccharide unit of the sugar moieties. In the ^{13}C NMR and DEPT spectra, two olefinic carbon signals at δ_C 114.4 (d) and 147.7 (s) were observed in the aglycone of **7**, instead of a methylene and a methine resonances at C-7 (δ_C 25.7) and C-8 (δ_C 45.6) in 26-deoxyactein, respectively. Thus, the aglycone of **7** was a 7,8-dehydro derivative of the corresponding analogue, which were supported by HMBC correlations of H-6 (δ_H 1.75) with C-7 (δ_C 114.4), C-8 (δ_C 147.7) and of H₃-28 (δ_H 1.02) and H₂-11 (δ_H 1.21, 2.91) with C-8. Similarly, HMBC correlation between H-1'' (δ_H 5.30) and δ_C C-3' (87.4) indicated the additional xylosyl residue was connected to C-3'. Furthermore, the disaccharide unit was located at C-3 by the HMBC correlation of H-1' (δ_H 4.77) with C-3 (δ_C 88.4). And the configurations of the sugar units were both determined to be β by the coupling constants ($J=7.2, 7.3$ Hz), respectively. In addition, the configuration of C-23 was assigned as *S* by detail comparison the known compound 26-deoxyactein (Chen et al., 2002a,b) which was secured by X-ray spectrum analysis. Hence, the structure of **7** was elucidated as 26-deoxyacetylacteinol-7(8)-en-3-*O*- β -D-xylopyranosyl-3'-*O*- β -D-xylopyranoside.

Compound **8** was purified as a white powder, and the molecular formula of $C_{42}H_{64}O_{15}$ was deduced from the HR-ESIMS at m/z 831.4140 $[M+Na]^+$. Analysis of the NMR spectroscopic data (Tables 1 and 2) revealed that the structure of **8** closely resembled those of 2'-*O*-acetylactein (Zhu et al., 2001), except for the sugar moieties. A 3-*O*- β -D-xylopyranosyl-3'-*O*- β -D-xylopyranoside unit was observed by comparison of the 1D and 2D NMR data with those of **7**. Its location was determined by the HMBC correlation between H-1' (δ_H 4.79, d, $J=7.5$ Hz) and C-3 (δ_C 88.3). Additionally, the configuration of C-23 was further determined as *R* by comparison the known compound 26-deoxyactein (Chen et al., 2002a,b). Thus,




Fig. 4. Major HMBC (→) and 1H - 1H COSY (←) correlations of **4**.

Table 3
Cytotoxicity compounds **1–8** (IC₅₀ values, μM).

No.	HL-60	SMMC-7721	A-549	MCF-7	SW480
1	>40	>40	>40	>40	>40
2	3.32	3.17	2.61	2.93	3.11
3	13.70	30.29	29.62	14.80	17.24
4	8.00	8.93	11.40	8.66	15.09
5	32.12	15.63	33.22	18.27	20.68
6	>40	>40	>40	>40	>40
7	16.57	29.86	18.40	16.16	15.72
8	27.80	28.52	>40	24.93	>40
Cisplatin ^a	1.01	5.29	6.13	13.62	14.03

^a Cisplatin were used as positive control.

the structure of **8** was determined as acteol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside.

The known compounds were identified as cimiacerogenin B (**9**) (Kusano et al., 1998), 12-*O*-acetyl-25-anhydrocimigenol-3-*O*-β-*D*-xylopyranoside (**10**) (Chen et al., 2002a,b), cimigenol-3-*O*-β-*D*-xylopyranoside (**11**) (Li et al., 1994), 25-*O*-acetylcimigenol-3-*O*-β-*D*-xylopyranoside (**12**) (Kadota et al., 1995), 12β-hydroxylcimigenol-3-*O*-β-*D*-xylopyranoside (**13**) (Yoshimitsu et al., 2006), 12β-hydroxycimigenol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside (**14**) (Kusano et al., 1976), 26-deoxyactein (**15**) (Chen et al., 2002a,b), and 26-deoxyacetylacteol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside (**16**) (Sun et al., 2008), by comparing their physical and spectroscopic data with those reported values.

Eight new compounds isolated in the present study were evaluated for their cytotoxicity against five human cancer cell lines (HL-60, SMMC-7721, A-549, MCF-7 and SW480) using MTT method. Compound **2** showed promising cytotoxic activities against SMMC-7721, A-549, MCF-7 and SW480 cell lines with IC₅₀ values of 3.17, 2.61, 2.93, and 3.11 μM (Table 3), respectively, compared to positive control (cisplatin, IC₅₀ 5.29, 6.13, 13.62, 14.03). Meanwhile, compounds **3–5** and **7** had moderate to weak inhibitory effects against five tested human cancer cell lines, with IC₅₀ values range from 8.0 to 33.2 μM (Table 3). These data suggest that some of the chemical constituents from this species might be valuable antitumor promoters and show supportive evidence for the theory of Chinese Medicine about cancer.

3. Experimental

3.1. General

Optical rotations were measured in MeOH with a Horiba SEAP-300 polarimeter. ¹H and ¹³C NMR spectra were recorded in pyridine-*d*₅ on Bruker DRX-500 and Avance III-600 MHz spectrometers (Bruker, Zürich, Switzerland), using TMS as internal standard for chemical shifts. Chemical shifts (δ) were expressed in ppm with reference to the TMS resonance. ESIMS, HRTOF-ESIMS and EIMS, HREIMS data were obtained using a VG Autospec-3000 and API QSTAR TOF spectrometer, respectively. Infrared spectra were recorded on a Shimadzu IR-450 instrument with KBr pellets. Thin-layer chromatography was performed on precoated TLC plates (Silica gel GF254, Qingdao Marine Chemical, Inc.) and spots were visualized by heating after spraying with 10% H₂SO₄ in EtOH. Semipreparative HPLC was performed on an Agilent 1100 liquid chromatograph with a YMC-Pack Pro C18 RS 10 mm × 250 mm column. Silica gel (mesh 200–300, Qingdao Marine Chemical, Inc.), Lichroprep RP-18 (40–63 μm, Merck), Amberlite IR-35 (10 μm) column and Sephadex LH-20 (Pharmacia) were used for column chromatography.

3.2. Plant materials

The roots of *Cimicifuga foetida* L. (82 kg) were collected from Yulong County, Yunnan Province, in September 2010 and identified by Professor Shengji Pei, Kunming Institute of Botany, Chinese Academy of Sciences. A voucher specimen (KUN No. 20100906) has been deposited at the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, PR China.

3.3. Extraction and isolation

The air-dried roots of *C. foetida* (82 kg) were crushed with a blender and refluxed with 95% EtOH for three times (5 h, each). The residue yielded by removal of the solvent was dissolved in water to form a suspension. The aqueous suspension was successively partitioned with EtOAc and *n*-BuOH. The EtOAc (5.6 kg) fraction was absorbed on 12 kg silica gel and chromatographed on a prepacked (120 kg) silica gel column, eluting stepwise with CHCl₃-MeOH (1:0, 100:1, 50:1, 20:1, 5:1) to give five fractions (A-E). Fraction C (230 g) was subjected to column chromatograph (CC) on silica gel (1.5 kg) and eluted with PE-Me₂CO (5:1, 2:1, 0:1) to obtain C1, C2, C3 and C4. Fraction C2 (40 g) was purified using an ODS silica gel column with MeOH-H₂O, followed by purification using semi-preparative HPLC eluted with CH₃CN-H₂O (60:40), furnished **1** (3.0 mg) and **9** (5.3 mg). Fraction D (200 g) was separated on silica gel eluted with CHCl₃-Me₂CO (15:1 to 5:1) to give ten sub-fractions (D1-D10). Fraction D1 (10 g) was separated by CC (ODS silica gel) with MeOH-H₂O (60:40 to 90:10) and purified by HPLC eluting with CH₃CN-H₂O (45:55) to obtain **2** (5.9 mg) and **10** (10.0 mg). Fraction D3 (5 g) was separated over CC (Sephadex LH-20, MeOH), and further treated by CC (ODS silica gel) with MeOH-H₂O (60:40 to 90:10), followed by purification using semi-preparative HPLC with CH₃CN-H₂O (50:50) to obtain **13** (20.5 mg). Fraction D6 was subjected to silica gel (CH₂Cl₂-MeOH, gradient from 25:1 to 15:1) and then purified by an ODS silica gel column to obtain **11** (15.3 mg) and **12** (10.6 mg). Fraction E (20 g) was also divided into five fractions (E1-E5), after performing ODS column (MeOH-H₂O, gradient from 40:60 to 70:30). Repeated CC of fraction E2 using silica gel CHCl₃-MeOH (15:1 to 8:1) and semi-preparative HPLC (CH₃CN-H₂O, 32:68) to afford **3** (13.2 mg), **5** (8.4 mg), **7** (7.8 mg) and **8** (23.4 mg). Similarly, compound **4** (10.6 mg), **6** (36.8 mg), **14** (8.5 mg), **15** (11.6 mg), and **16** (20.5 mg) were isolated from E4 and E5 by repeated CC, respectively.

3.3.1. Cimiacerol-1(2)-en-3-one

White powder; [α]_D²⁰ -138.6 (c 0.1, MeOH); IR (KBr) ν_{max} 3441, 1667, 1641, 1459, 1375, 1237, 1240, 1167, 1072, 1046, 980 cm⁻¹; ¹H and ¹³C NMR data see Tables 1 and 2; HREIMS *m/z* 484.3168 [M]⁺ (calcd for 484.3189).

3.3.2. 25-*O*-methyl-24-*O*-acetylisodahurinol-3-*O*-β-*D*-xylopyranoside (**2**)

White powder; [α]_D²⁰ +55.89 (c 0.03, MeOH); IR (KBr) ν_{max} 3433, 2938, 2872, 1743, 1631, 1457, 1373, 1237, 1161, 1047, 971 cm⁻¹; ¹H (C₅D₅N, 600 MHz) and ¹³C NMR (C₅D₅N, 150 MHz) data see Tables 1 and 2; ESIMS *m/z* 699 [M+Na]⁺; HRESIMS *m/z* 699.4074 (calcd for 699.4084).

3.3.3. 12-*O*-acetyl-25-anhydrocimigenol-3-*O*-β-*D*-xylopyranosyl-3'-*O*-β-*D*-xylopyranoside (**3**)

White powder; [α]_D²⁰ -51.76 (c 0.01, MeOH); IR (KBr) ν_{max} 3441, 2931, 2871, 1735, 1632, 1456, 1383, 1240, 1169, 1043, 985 cm⁻¹; ¹H

(C₅D₅N, 600 MHz) and ¹³C NMR (C₅D₅N, 150 MHz) data see Tables 1, 2; HRESIMS *m/z* 815.4180 [M+Na]⁺ (calcd for 815.4194).

3.3.4. 2'-O-acetylcimigenol-3-O-β-D-xylopyranosyl-3'-O-β-D-xylopyranoside (4)

White powder; [α]_D²⁰ +1.21 (c 0.02, MeOH); IR (KBr) ν_{max} 3441, 2966, 2935, 2870, 1739, 1632, 1459, 1383, 1242, 1171, 1042, 979 cm⁻¹; ¹H (C₅D₅N, 600 MHz) and ¹³C NMR (C₅D₅N, 150 MHz) data see Tables 1 and 2; ESIMS *m/z* 817 [M+Na]⁺; HRESIMS *m/z* 817.4339 (calcd for 817.4350).

3.3.5. Cimilactone K (5)

White powder; [α]_D²⁰ -87.44 (c 0.01, MeOH); IR (KBr) ν_{max} 3440, 2934, 2885, 1719, 1632, 1461, 1383, 1366, 1247, 1082, 1041, 989 cm⁻¹; ¹H (C₅D₅N, 600 MHz) and ¹³C NMR (C₅D₅N, 600 MHz) data see Tables 1 and 2; ESIMS *m/z* 745 [M+Na]⁺; HRESIMS *m/z* 745.3765 (calcd for 745.3775).

3.3.6. 23-O-acetylshengmanol-3-O-β-D-xylopyranosyl-3'-O-β-D-xylopyranoside (6)

White powder; [α]_D²⁰ -46.97 (c 0.02, MeOH); IR (KBr) ν_{max} 3440, 2936, 2871, 1737, 1632, 1459, 1382, 1241, 1170, 1043, 993 cm⁻¹; ¹H (C₅D₅N, 600 MHz) and ¹³C NMR (C₅D₅N, 150 MHz) data see Tables 1 and 2; ESIMS *m/z* 817 [M+Na]⁺; HRESIMS *m/z* 817.4342 (calcd for 817.4350).

3.3.7. 26-Deoxyacetylacteol-7(8)-en-3-O-β-D-xylopyranosyl-3'-O-β-D-xylopyranoside (7)

White powder; [α]_D²⁰ -101.3 (c 0.01, MeOH); IR (KBr) ν_{max} 3442, 2932, 2877, 1731, 1632, 1456, 1384, 1246, 1164, 1044, 987 cm⁻¹; ¹H (C₅D₅N, 600 MHz) and ¹³C NMR (C₅D₅N, 150 MHz) data see Tables 1 and 2; ESIMS *m/z* 813 [M+Na]⁺; HRESIMS *m/z* 813.4029 (calcd for 813.4037).

3.3.8. Acteol-3-O-β-D-xylopyranosyl-3'-O-β-D-xylopyranoside (8)

White powder; [α]_D²⁰ -69.54 (c 0.01, MeOH); IR (KBr) ν_{max} 3442, 2934, 2875, 1732, 1634, 1454, 1383, 1244, 1169, 1131, 1046, 988 cm⁻¹; ¹H (C₅D₅N, 600 MHz) and ¹³C NMR (C₅D₅N, 150 MHz) data see Tables 1 and 2; ESIMS *m/z* 831 [M+Na]⁺; HRESIMS *m/z* 831.4140 (calcd for 831.4143).

3.4. Hydrolysis and identification of sugar residue in the new compounds 2–8

The new compounds 2–8 (4 mg of each) were dissolved in MeOH (5 ml) and refluxed with 0.5 N HCl (3 ml) for 4 h. Each reaction mixture was diluted with H₂O and extracted with CHCl₃ (3 × 10 ml). The water layer was then neutralized by Ag₂CO₃, and the precipitate filtered to give a monosaccharide. Each monosaccharide of those compounds had an R_f (EtOAc/CHCl₃/MeOH/H₂O, 3:2:2:1) and specific rotation [α]_D²⁰ +24.3 (c 0.10, H₂O) corresponding to those of D-xylose (Sigma-Aldrich).

3.5. Cytotoxicity bioassay

Five human cancer cell lines, including human myeloid leukemia HL-60, hepatocellular carcinoma SMMC-7721, lung cancer A-549, breast cancer MCF-7 and colon cancer SW480, were used in the cytotoxic assay. Cells were cultured in DMEM medium (Hyclone, USA), supplemented with 10% fetal bovine serum (Hyclone, USA), in 5% CO₂ at 37 °C. The cytotoxicity assay was conducted according to the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] method in 96-well microplates (Mossmann, 1983; Alley et al., 1938). Exactly 100 μl of adherent cells was seeded into each

well of 96-well cell culture plates and allowed to adhere for twelve hours before addition of test compounds, while suspended cells were seeded just before drug addition with initial density of 1 × 10⁵ cells/mL. Each cancer cell line was exposed to the compounds dissolved in DMSO at five different concentrations in triplicate for 48 h, with cisplatin as positive controls. After compound treatment, cell viability was detected and a cell growth curve was graphed. IC₅₀ values were calculated by Reed and Muench's method (Reed and Muench, 1938).

Acknowledgements

This research work was supported by Program for National Natural Science Foundation of China (No. U1132604), The Major Program of CAS (No. KZDZEW-Z-004-03), as well as Foundation of State Key Laboratory of Phytochemistry and Plant Resources in West China (P2015-ZZ01). Authors also were particularly grateful to Research Group of Prof. & Dr. Yan Li for bioassay tests of cytotoxic activity.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.phytol.2016.06.002>.

References

- Alley, M.C., Scudiero, D.A., Monks, A., 1938. Feasibility of drug screening with panels of human-tumor cell-lines using microculture tetrazolium assay. *Cancer Res.* 27, 493–497.
- Chen, S.N., Fabricant, D.S., Lu, Z.Z., Fong, H.H.S., Farnsworth, N.R., 2002a. Cimicifugosides I-P, new 9,19-cyclolanostane triterpene glycosides from *Cimicifuga racemosa*. *J. Nat. Prod.* 65, 1391–1397.
- Chen, S.N., Li, W.K., Fabricant, D.S., Santarsiero, B.D., Mesecar, A., 2002b. Isolation, structure elucidation, and absolute configuration of 26-deoxyactein from *Cimicifuga racemosa* and clarification of nomenclature associated with 27-deoxyactein. *J. Nat. Prod.* 65, 601–605.
- Chen, J.Y., Li, P.L., Tang, X.L., Wang, S.J., Jiang, Y.T., Shen, L., Xu, B.M., Shao, Y.L., Li, G.Q., 2014. Cycloartane triterpenoids and their glycosides from the rhizomes of *Cimicifuga foetida*. *J. Nat. Prod.* 77, 1997–2005.
- Compton, J.A., Culham, A., Gibbings, J.G., Jury, S.L., 1998. Phylogeny of *Actaea* including *Cimicifuga* (Ranunculaceae) inferred from nrDNA ITS sequence variation. *Biochem. Syst. Ecol.* 26, 185–197.
- Kadota, S., Li, J.X., Tanaka, K., Namba, T., 1995. Constituents of *Cimicifuga* rhizoma II. Isolation and structures of new cycloartenol triterpenoids and related compounds from *Cimicifuga foetida* L. *Tetrahedron* 51, 1143–1166.
- Kusano, G., Murakami, Y., Sakurai, N., Takemoto, T., 1976. Studies on the constituents of *Cimicifuga* spp. XI. Isolation and stereostructures of Dahurinol, dehydroxydahurinol and 25-O-methylisodahurinol. *Yakugaku Zasshi* 96, 82–85.
- Kusano, A., Takahira, M., Shibano, M., Miyase, T., Okuyama, T., Kusano, G., 1998. Structure of two new cyclolanostanol xyloides, cimicifugosides A and B. *Heterocycles* 48, 1003–1013.
- Kusano, A., Shibano, M., Kusano, G., 1999. Studies on the constituents of *Cimicifuga* species. XXVII. Malonyl cyclolanostanol glycosides from the underground parts of *Cimicifuga simplex* worms. *Chem. Pharm. Bull.* 47, 1175–1179.
- Li, J.X., Yu, Z.Y., 2006. *Cimicifuga* rhizome: from origins, bioactive constituents to clinical outcomes. *Curr. Med. Chem.* 13, 2927–2951.
- Li, C.J., Li, Y.H., Chen, S.F., Xiao, P.G., 1994. Triterpenoids from *Cimicifuga foetida* L. *Acta Pharm. Sin.* 29, 449–453.
- Liu, Y., Chen, D., Si, J.Y., Tu, G.Z., An, D.G., 2002. Two new cyclolanostanol xyloides from the aerial parts of *Cimicifuga dahurica*. *J. Nat. Prod.* 65, 1486–1488.
- Lu, L., Chen, J.C., Li, Y., Qing, C., Wang, Y.Y., Nian, Y., Qiu, M.H., 2012. Studies on the constituents of *Cimicifuga foetida* collected in Guizhou Province and their cytotoxic activities. *Chem. Pharm. Bull.* 60, 571–577.
- Mossmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods* 65, 55–63.
- Nian, Y., Zhang, Y.L., Chen, J.C., Lu, L., Qiu, M.H., Qing, C., 2010. Cytotoxic chemical constituents from the roots of *Cimicifuga foetida*. *J. Nat. Prod.* 73, 93–98.
- Nian, Y., Zhang, X.M., Li, Y., Wang, Y.Y., Chen, J.C., Lu, L., Zhou, L., Qiu, M.H., 2011. Cycloartane triterpenoids from the aerial parts of *Cimicifuga foetida* Linnaeus. *Phytochemistry* 72, 1473–1481.
- Nian, Y., Wang, H.Y., Su, J., Zhou, L., Qiu, M.H., 2012. A cytotoxic 4α-methyl steroid from the aerial parts of *Cimicifuga foetida* L. *Fitoterapia* 83, 293–297.
- Pharmacopoeia of the People's Republic of China Vol.1; Medicine Science and Technology Press of China: Beijing, 2010; p. 68.

- Reed, L.J., Muench, H., 1938. A simple method of estimating fifty percent endpoints. *Am. J. Hyg.* 27, 493–497.
- Shao, Y., Harris, A., Wang, M.F., Zhang, H.J., Cordell, G.A., Bowman, M., Lemmo, E., 2000. Triterpene glycosides from *Cimicifuga racemosa*. *J. Nat. Prod.* 63, 905–910.
- Sun, L.R., Yan, J., Nian, Y., Zhou, L., Zhang, H.J., Qiu, M.H., 2008. New triterpene diglycosides from the rhizome of *Cimicifuga foetida*. *Molecules* 13, 1712–1721.
- Tian, Z., Pan, R.L., Chang, Q., Si, J.Y., Xiao, P.G., Wu, E.X., 2007. *Cimicifuga foetida* extract inhibits proliferation of hepatocellular cells via induction of cell cycle arrest and apoptosis. *J. Ethnopharmacol.* 114, 227–233.
- Yoshimitsu, H., Nishida, M., Sakaguchi, M., Nohara, T., 2006. Two new 15-deoxycimigenol-type and three new 24-*epi*-Cimigenol-type glycosides from *Cimicifuga* rhizome. *Chem. Pharm. Bull.* 54, 1322–1325.
- Zhou, L., Yang, J.S., Tu, G.Z., Zou, J.H., 2006. Cyclolanostane triterpene glycosides from *Souliea vaginata*. *Chem. Pharm. Bull.* 54, 823–826.
- Zhu, N.Q., Jiang, Y., Wang, M.F., Ho, C.T., 2001. Cycloartane triterpene saponins from the roots of *Cimicifuga foetida*. *J. Nat. Prod.* 64, 627–629.